The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2025 | Novel CAR-T constructs on the horizon for multiple myeloma
In this interview, Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, briefly comments on novel CAR T-cell constructs being explored in multiple myeloma (MM), namely anitocabtagene autoleucel (anito-cel). Anito-cel has shown effectiveness and a potentially reduced risk of late neurotoxicity, a concern with the currently used product ciltacabtagene autoleucel (cilta-cel). Additionally, Prof. Einsele mentions dual-targeting constructs, which may mitigate antigen loss, an issue affecting approximately 5% of patients receiving CAR-T. This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting, held in Strasbourg, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
Yeah, there is clearly, there are new constructs like anito-cel, which is a construct that is also going into now randomized trials. And this product seems, which has a different binding domain when compared to the commercial, currently available commercial CAR T-cell products, probably a lower affinity binding and therefore still very effective. So, it has the effectiveness, nearly, of cilta-cel, but without having these late neurotoxicity issues that in some patients with cilta-cel has actually been observed...
Yeah, there is clearly, there are new constructs like anito-cel, which is a construct that is also going into now randomized trials. And this product seems, which has a different binding domain when compared to the commercial, currently available commercial CAR T-cell products, probably a lower affinity binding and therefore still very effective. So, it has the effectiveness, nearly, of cilta-cel, but without having these late neurotoxicity issues that in some patients with cilta-cel has actually been observed. So, this is one interesting construct.
And there are a lot of constructs that are now providing a dual targeting, which might also be interesting in reducing the risk of antigen loss, which occurs in about 5% of patients that receive CAR T-cell therapy. So also new constructs are coming.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
